N/A N=80 Femoral Triangle and Adductor Canal Blocks Versus Femoral Nerve Block for Total Knee Arthroplasty
Total Knee Arthroplasty
Primary: Extent of Motor Blockade — 18; 29; 13; 5 Participants — p=<0.01
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=100 Post-Operative Colonization Rates of Femoral Nerve Catheters Treated With Chlorhexidine-Impregnated Patch
Catheter Infections · Spinal Catheter (Epidural) (Subdural); Complications, Infection or Inflammation
Primary: Catheter Tip Colonization — 2; 3 participants
N/A N=38 Observational Study of Deferiprone (Ferriprox®) in the Treatment of Superficial Siderosis
Superficial Siderosis
Primary: Number of Participants Who Show Stability, Improvement or Decline in Self Reported Hearing — 13; 18; 0 Participants
N/A N=60 Saphenous Nerve Block vs. Femoral Nerve Block for Total Knee Arthroplasty
Difference Between Femoral Nerve Block and Saphenous Block
Primary: Visual Analogue Scale Pain Score — 2.81; 2.47 units on a scale
Phase 2 N=10 Rilonacept to Improve Artery Function in Patients With Atherosclerosis
Coronary Artery Disease · Atherosclerosis · Inflammation
Primary: C-Reactive Protein (CRP) — 3.7; 4.6 mg/L
N/A N=150 IN.PACT Admiral Drug-Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Superficial Femoral Artery (SFA) and Proximal Popliteal Artery (PPA)
Femoral Artery Stenosis · Popliteal Artery Stenosis · Femoral Artery Occlusion
Primary: Primary Patency — 82.2; 52.4 Percentage of participants — p=<0.001
N/A N=528 ELUVIA™ Drug-eluting Stent Versus Zilver® PTX® Stent
Atherosclerosis of Native Arteries of the Extremities
Primary: Percentage of Participants With Major Adverse Events (MAEs) — 0; 0; 0; 0 percentage of participants — p=<0.0001
Phase 2 N=27 Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer
Bladder Cancer
Primary: Maximum Tolerated Dose (MTD) of Chemophase in Combination With MMC — 800000 Units
N/A N=250 S.M.A.R.T.® Nitinol Self-Expandable Stent in the Treatment of Obstructive Superficial Femoral Artery Disease
Superficial Femoral Artery Disease
Primary: 12-month Primary Patency Rate — 143; 72 participants — p=0.437
N/A N=264 Comparison of the SUpera® PERipheral System in the Superficial Femoral Artery
Peripheral Vascular Disease
Primary: Primary Safety Endpoint: Freedom From Death, Target Lesion Revascularization (TLR), or Any Amputation of the Index Limb to 30 (±7) Days. — 99.2; 99.6; 99.6; 100.0…
N/A N=76 CVT-SFA First in Human Trial for Treatment of Superficial Femoral Artery or Proximal Popliteal Artery
Femoral Artery Stenosis · Popliteal Artery Stenosis · Femoral Artery Occlusion
Primary: Number and Percentage of Participants With Freedom of Major Adverse Event (MAE) Rate — 72 Participants
N/A N=276 A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
Peripheral Vascular Disease
Primary: Primary Effectiveness Endpoint — 54.0 percentage of stent patency
N/A N=57 Stenting of the Superficial Femoral and/or Proximal Popliteal Artery Project
Atherosclerosis of Native Arteries of the Extremities
Primary: Primary Patency — 94.4 percentage of lesions
Phase 3 N=440 RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
Peripheral Artery Disease · Atherosclerosis · Artery Diseases, Peripheral
Primary: Number of Participants With Primary Lesion Patency — 194; 57; 43 Participants — p=0.0017
N/A N=160 The Effectiveness of a Telehealth Program on Cardiac Symptom Distress, Self-care and Quality of Life of Patients With Coronary Artery Disease After Coronary Artery Bypass Surgery: A Randomized Study
Telehealth · Coronary Artery Bypass Surgery
Primary: Cardiac Symptom Distress Score — 15.24; 12.84; 12.81; 11.87 scores on a scale